XNAS · Healthcare · Biotechnology
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.79 | 3.24 | +310.13% | $1.51B | ✅ Beat | +1.31% | +1.03% | — |
| 2026-02-26 | Q4 2025 | 1.42 | 1.95 | +37.32% | $1.50B | ✅ Beat | -5.46% | -9.13% | -12.20% |
| 2025-11-06 |
| Q3 2025 |
| 0.80 |
| 2.65 |
| +231.25% |
| $1.41B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.35 | 2.25 | +542.86% | $1.32B | ✅ Beat | — | — | — |
| 2025-02-27 | Q4 2024 | -1.02 | -1.43 | -40.20% | $1.13B | ❌ Miss | -2.36% | -7.69% | -2.23% |
| 2024-08-07 | Q2 2024 | -2.33 | -1.15 | +50.64% | $929.2M | ✅ Beat | — | — | — |
| 2024-05-08 | Q1 2024 | -2.89 | -2.41 | +16.61% | $751.7M | ✅ Beat | — | — | — |
| 2024-02-26 | Q4 2023 | -3.73 | -3.53 | +5.36% | $634.4M | ✅ Beat | — | — | — |
Showing last 8 quarters.